Benzodiazepines for the Treatment of Seizure Clusters
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Patients with epilepsy may experience seizure clusters, which are described by the US Food and Drug Administration (FDA) as intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern. Untreated seizure clusters may increase the risk for status epilepticus, as well as decrease quality of life and increase burden on patients and care partners. Benzodiazepine therapies are the mainstay for acute treatment of seizure clusters and are often administered by nonmedical care partners outside a healthcare facility. Three rescue therapies are currently FDA-approved for this indication, with diazepam rectal gel being the first in 1997, for patients aged ≥ 2 years. Limitations of rectal administration (e.g., positioning and disrobing the patient, which may affect ease of use and social acceptability; interpatient variation in bioavailability) led to the investigation of the potential for nasal administration as an alternative. Midazolam nasal spray (MDS) was approved by the FDA in 2019 for patients aged ≥ 12 years and diazepam nasal spray (DNS) in 2020 for patients aged ≥ 6 years; these two intranasal therapies have differences in their formulations [e.g., organic solvents (MDS) vs. Intravail and vitamin E for absorption and solubility (DNS)], effectiveness (e.g., proportion of seizure clusters requiring only one dose), and safety profiles. In clinical studies, the proportion of seizure clusters for which only one dose of medication was used varied between the three approved rescue therapies with the highest single-dose rate for any time period for DNS; however, although studies for all three preparations enrolled patients with highly intractable epilepsy, inclusion and exclusion criteria varied, so the three cannot be directly compared. Treatments that have been used off-label for seizure clusters in the USA include midazolam for injection as an intranasal spray (indicated for sedation/anxiolysis/amnesia and anesthesia) and tablet forms of clonazepam (indicated for treatment for seizure disorders) and lorazepam (indicated for anxiety). In the European Union, buccal and intranasal midazolam are used for treating the indication of prolonged, acute convulsive seizures and rectal diazepam solution for the indication of epileptic and febrile convulsions; duration of effectiveness for these medications for the treatment of seizure clusters has not been established. This paper examines the literature context for understanding seizure clusters and their treatment and provides effectiveness, safety, and administration details for the three FDA-approved rescue therapies. Additionally, other medications that are used for rescue therapy in the USA and globally are discussed. Finally, the potential benefits of seizure action plans and candidates for their use are addressed. This paper is intended to provide details about the unique characteristics of rescue therapies for seizure clusters to help clarify appropriate treatment for individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term BZD use may also be appropriate for medical conditions such as complex seizure disorders,42 spasticity,43,44 sleep disorders involving abnormal movements (e.g., rapid eye movement (REM) sleep behavior disorder, restless leg syndrome),45 and catatonia.46,47”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-hospital benzodiazepine administration may be effective in controlling repetitive seizures or status epilepticus and avoid hospitalization 212,213 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [213]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 83 · Cited by 30
Research works printed but not linked: 10
- Bausch Health US, LLC. Diastat® C-IV (diazepam rectal gel). Full Prescribing Information. Bridgewater: Bausch Health US, LLC; 2023.
- Neurelis, Inc. VALTOCO® (diazepam nasal spray). Full Prescribing Information. San Diego: Neurelis Inc; 2023.
- UCB, Inc. Nayzilam® (midazolam nasal spray). Full Prescribing Information. Smyrna: UCB Inc; 2023.
- Lepkowski AM. School nursing evidence-based practice clinical guideline: students with seizures and epilepsy. Silver Spring: National Association of School Nurses; 2018.
- Hospira, Inc. Midazolam injection (midazolam injection) Full Prescribing Information. Lake Forest: Hospira Inc; 2023.
- Genentech USA, Inc. Klonopin (clonazepam). Full Prescribing Information. South San Francisco: Genentech USA Inc; 2021.
- Bausch Health US L. Ativan (Lorazepam tablets). Full Prescribing Information. Bridgewater: Bausch Health US, LLC; 2023.
- Akorn. Lorazepam oral concentrate. Full prescribing information. Gurnee: Akorn Operating Company LLC; 2022.
- Hikma Pharmaceuticals USA Inc. ATIVAN (lorazepam injection). Full Prescribing Information. Berkeley Heights: Hikma Pharmaceuticals USA Inc.; 2021.
- Medir Europe BV. Nasolam (Midazolam nasal spray). Summary of Product Characteristics. Medir Europe B; 2022.
Metadata
- Authors
- Penovich, P. E., Rao, V. R., Long, L., Carrazana, E., & Rabinowicz, A. L.
- Affiliations
- Minnesota Epilepsy Group (US)
- University of California, San Francisco (US)
- The Ohio State University Wexner Medical Center (US)
- University of Hawaiʻi at Mānoa (US)
- Corresponding author
- Penovich, Patricia E.
- Venue
- CNS Drugs
- Published
- 2024-02
- Volume
- 38
- Issue
- 2
- Pages
- 125-140
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC10881644
- OpenAlex
- W4391843822
- Cited by
- 30
- References
- 83
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 7
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor, 14 d)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Neurelis, Inc.
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- seizure clusters, benzodiazepines, salvage therapy, status epilepticus, intranasal administration, clonazepam, lorazepam, epilepsy, drug safety, medication administration, pediatric patients, febrile seizures
- MeSH terms
- Administration, Intranasal, Anticonvulsants, Benzodiazepines, Diazepam, Epilepsy, Epilepsy, Generalized, Humans, Midazolam, Quality of Life, Status Epilepticus, Nasal Sprays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepines for the Treatment of Seizure Clusters. https://app.cochat.ai/papers/10.1007/s40263-023-01060-1
- The paper
- Penovich, P. E., Rao, V. R., Long, L., Carrazana, E., & Rabinowicz, A. L. (2024). Benzodiazepines for the Treatment of Seizure Clusters. CNS Drugs. https://doi.org/10.1007/s40263-023-01060-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.